|
 |
AmprenavirThis page contains recent news articles, when available, and an overview of Amprenavir but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Amprenavir (when available) Amprenavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Amprenavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs. For the treatment of HIV-1 infection in combination with other antiretroviral agents Mechanism Of Action: Amprenavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. News Articles on Amprenavir Brand Names/Synonyms: Amprenavir is also known by the following brand names and/or synonyms141w94, Kvx-478, Agenerase, Prozei,; Agenerase; Amprenavir; Lexiva; VX-478 Drug Category: Amprenavir is categorized under the following by the FDA: Anti-HIV Agents; Antibiotics; Anti-HIV Agents; ATC:J05AE05; ATC:J05AE07 Dosage Forms: CAPSULE Absorption: Not Available Interactions: [an error occurred while processing this directive] Chemical IUPAC Name: tetrahydrofuran-3-yl[3-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-1-benzyl-2-hydroxy-propyl]aminomethanoate |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |